The Centenary Institute's cytometry research program last night received the $1 million Ramaciotti Biomedical Research Award. As a result of the award, the Ramaciotti Centre for Human Systems Biology will be established. [ + ]

Qiagen has launched the Empowered Genome Community - an initiative to help people who have had their genomes sequenced share, explore and interpret their data with researchers and each other. [ + ]

Innate Immunotherapeutics has moved its base from Auckland to Sydney as it prepares for Australian phase IIb trials of SPMS treatment candidate MIS416. [ + ]

The 2013 recipients of the biennial Ramaciotti Awards for biomedical research have been announced. [ + ]

Results from a pilot trial of Ellex Medical Lasers' (ASX:ELX) Retinal Rejuvenation Therapy (2RT) suggest the treatment could act as an early intervention therapy for AMD. [ + ]

A month after licensing MoxDuo IR for ANZ and Oceania to Aspen for $1.25m, QRxPharma (ASX:QRX) has expanded the deal to also cover South Africa. [ + ]

Austrade, in partnership with Australian federal and state government agencies, is organising the first Australian 'Innovation Week' in India and invites interested Australian companies to participate. While the entire program will run over three weeks, the life sciences component will run for one week, commencing 25 November 2013. [ + ]

Brisbane's new biomedical research institute, Translational Research Institute, has been officially opened by the Governor-General, Her Excellency the Honourable Quentin Bryce. [ + ]

Biotech company Roche plans to invest 800 million Swiss francs within its global manufacturing network to increase production capabilities for its biologic medicines over the next five years. [ + ]

Genetic research reveals Barrett's oesophagus and oesophageal cancer are more closely linked than previously thought. [ + ]

Starpharma's (ASX:SPL) DEO, a formulation of colon and colorectal cancer drug oxaliplatin, has demonstrated reduced neurotoxicity in lab trials comparing it to the original version. [ + ]

Research from the University of Melbourne and the Florey Institute could be developed into a new class of drugs for neurodegenerative diseases. [ + ]

Mesoblast (ASX:MSB) will pay up to US$100m to acquire the mesenchymal precursor cell business of US-based Osiris Therapeutics. [ + ]

The brown recluse spider (Loxosceles recluse) produces superthin ribbons of silk, as opposed to the round fibres typically spun by spiders. In a world first, scientists have examined the silk and found that its properties may be suitable for a variety of applications. [ + ]

The University of Melbourne has entered into a drug development deal with Procypra Therapeutics, a US start-up company established by Collaborative Medicinal Development under the umbrella of venture capital firm Cthulhu Ventures. [ + ]